Relmada Therapeutics boosts cash reserves for late-stage bladder cancer trial
The company ended the first quarter with $234.0 million in cash following a $160 million private investment in public equity financing.
Relmada Therapeutics (RLMD) increased its cash position to $234.0 million as of March 31, 2026. The biotechnology company, which focuses on developing therapies for bladder cancer, reported a significant liquidity increase from the $93.0 million held as of December 31, 2025.
The growth in capital was primarily driven by a $160 million private investment in public equity financing completed in March 2026. This funding provides a runway as the company transitions toward late-stage development of its lead candidate, NDV-01.
Relmada appointed Bipin Dalmia, PhD, MBA, as Chief Business Officer to lead corporate strategy, commercial planning, and business development. The appointment coincides with the company's push toward the commercialization phase of its pipeline.
To protect its intellectual property, the company filed a provisional patent application with the USPTO in April 2026. The application covers NDV-01 pharmaceutical formulations and methods of treatment, with a potential term extending until April 2047.
Relmada maintained guidance to initiate the Phase 3 RESCUE registrational program in mid-2026. The trial is designed for second-line BCG-unresponsive and adjuvant intermediate-risk non-muscle invasive bladder cancer.